Psyence Biomedical (PBM) Cash & Equivalents (2023 - 2025)

Psyence Biomedical's Cash & Equivalents history runs 3 years deep, the most recent figure standing at $7.1 million for Q3 2025.

• In Q3 2025, Cash & Equivalents rose 269.98% year-over-year to $7.1 million; the TTM figure through Sep 2025 stood at $7.1 million (up 269.98% YoY), while the FY2025 annual figure was $6.1 million, up 736.78% from the prior year.
• Cash & Equivalents was $7.1 million for Q3 2025 at Psyence Biomedical, up from $6.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $7.1 million in Q3 2025 to a low of $733188.0 in Q1 2024.
• Historically, Cash & Equivalents has averaged $3.5 million across 3 years, with a median of $1.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 45.05% in 2024, then surged 736.78% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $1.3 million in 2023, then jumped by 44.84% to $1.9 million in 2024, then surged by 269.98% to $7.1 million in 2025.
• The last three Cash & Equivalents figures came in at $7.1 million (Q3 2025), $6.1 million (Q1 2025), and $1.9 million (Q3 2024), per Business Quant data.